No Benefit of ACE Inhibitors/Statins for Teens with Type 1 Diabetes

Treatment with angiotensin-converting enzyme (ACE) inhibitors, statins, or both does not affect albumin excretion in adolescents with type 1 diabetes, concludes a trial in The New England Journal of Medicine.

In a screening study of 4407 adolescents with type 1 diabetes, 1287 had increased albumin excretion, defined as the upper third of the albumin-to-creatinine ratio. Of these, 443 were randomly assigned to treatment with an ACE inhibitor, statin, or matching placebo in a 2-by-2 factorial design. The main outcome of interest was change in albumin excretion, assessed every 6 months over 2 to 4 years. Secondary outcomes included microalbuminuria, retinopathy, lipid levels, and other cardiovascular risk markers.

Change in albumin-to-creatinine ratio over time was unaffected by treatment with ACE inhibitor and/or statin. The incidence of microalbuminuria was lower with ACE inhibitor compared to placebo, but this difference was not considered significant. Statin treatment was associated with expected changes in lipid levels. However, there were no between-treatment differences in carotid intima-media thickness, other cardiovascular risk markers, glomerular filtration rate, or retinopathy progression. No serious unexpected adverse reactions occurred.

In adolescents with type 1 diabetes, puberty-associated increases in albumin excretion occur before the development of microalbuminuria and macroalbuminuria. This suggests that ACE inhibitors or statins might have beneficial effects for young diabetics with high albumin excretion.

However, the randomized, placebo-controlled trial shows no significant difference in albumin-to-creatinine ratio for young patients with type 1 diabetes taking ACE inhibitors or statins. Aside from statin-induced changes in lipid profiles, secondary outcomes are also similar between groups.


Race Modifies HIV’s Impact on Dialysis Survival

Even with modern antiretroviral therapy (ART), survival on dialysis is significantly lower for non-white patients with HIV infection, according to a study in Kidney International.

Using data from a nationwide dialysis provider, the researchers identified two groups of HIV-positive dialysis patients: 5348 patients who had HIV only and 1863 patients with HIV and hepatitis C virus (HCV) coinfection. In both groups, a large majority of patients were African American: 74.3% of the HIV-positive group and 81.6% of the HIV/HCV-positive group. Percentages of Caucasian patients were 13.2% and 9.0%, respectively.

A cohort of 410,545 HIV/HCV-negative patients were studied for comparison: 47.6% Caucasian and 29.0% African American. The effects of HIV- and HIV/HCV-positive status on mortality were assessed, along with the possible modifying effects of race.

In Caucasians, HIV status was not significantly related to mortality, but HIV/HCV infection was hazard ratio (HR) 1.48. For non-Caucasians, both HIV- and HIV/HCV-positive status were associated with higher mortality: HR 1.44 and 1.77, respectively. The results were similar in secondary analyses using matched propensity scores.

The effects of HIV infection on dialysis outcomes are unclear, particularly in the era of widespread ART use. The new analysis suggests a “very concerning” reduction in survival associated with HIV-positive status in non-Caucasian patients: African American, Latino, Asian, and “other.”

Across racial/ethnic group, dialysis survival is reduced for patients with HIV/HCV coinfection. The authors discuss the need for interventions targeting these vulnerable populations, possibly including early nephrology referral and therapy for HCV [Sawinski D, et al. Race but not hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 2017; http://dx.doi.org/10.1016/j.kint.2017.08.015].